The technology could analyze, in one assay, all structural variants known to be diagnostic and prognostic for blood cancers, potentially replacing serial FISH testing.
The firms will develop tests in the hematology oncology space where detecting large structural variations of the genome is crucial for accurate diagnoses.
At AGBT, an early adopter of Bionano's technology discussed how his lab is using it in conjunction with NGS to diagnose rare diseases.
The company's Irys genome mapping technology provides researchers with a non-sequencing-based tool that is essential for studying structural variation.
BioNano plans to develop structural variant assays on its Irys system for diagnostic use in China as a first step in bringing its technology to the clinic.
The assays will incorporate BioNano's Irys next-generation mapping platform, which is designed to image, map, and analyze DNA at the single-molecule level.
The hybrid approach expands on one described last year by Mount Sinai researchers, and relies on short-read sequencing, linked-read sequencing, and genome mapping.
The companies will provide access to IrysSolve, BioNano's whole-genome analysis algorithms and pipeline, on DNAnexus' cloud platform.
Gene Company will distribute BioNano's Irys genome mapping system in China, except for Shanghai, with exclusive rights in Hong Kong and Macau.
A Mount Sinai-led team of researchers combined the technologies to generate de novo assemblies and get a better view of structural variations.
The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.
Kaiser Health News reports that gene therapies could cost more than a million dollars.
Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.
In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.